Recurrent ovarian cancer has a median survival of about two years when the cancer responds to platinum-based chemotherapy, and roughly 9 to 12 months when it does not. These numbers vary significantly depending on how long the first remission lasted, whether certain gene mutations are present, and which treatments are available. There is no single five-year survival rate for recurrent ovarian cancer because outcomes depend heavily on individual factors, but understanding the key variables can give you a much clearer picture.
Why Platinum Sensitivity Matters Most
The single biggest predictor of survival after recurrence is how your cancer responds to platinum-based chemotherapy, the standard first-line treatment. Oncologists divide recurrent ovarian cancer into two categories based on how long the first remission lasted.
If the cancer returns more than six months after finishing platinum chemotherapy, it is classified as platinum-sensitive. These cancers tend to respond well to another round of platinum-based treatment, and median survival is around 24 months from the time of recurrence. The longer the initial remission, the better the outlook. A woman whose cancer stayed in remission for two or three years before returning generally has a more favorable prognosis than someone whose cancer came back at seven months.
If the cancer returns within six months of platinum treatment, it is classified as platinum-resistant. A different chemotherapy regimen is used because the original drugs are unlikely to work again. Median survival for platinum-resistant recurrent ovarian cancer is 9 to 12 months, making it one of the most difficult scenarios in gynecologic oncology.
How BRCA Mutations Affect the Outlook
Women who carry BRCA1 or BRCA2 gene mutations have a notably different trajectory. Their cancers tend to respond better to platinum chemotherapy and to a class of drugs called PARP inhibitors, which block a DNA repair pathway that BRCA-mutated cancer cells depend on. A large meta-analysis found that BRCA-mutated patients had a five-year survival rate roughly 15 percentage points higher than non-carriers. At ten years, the gap narrowed to about 8.6 percentage points. And interestingly, among women who had already survived five years, BRCA status no longer predicted whether they would survive an additional five years. The early advantage appears to come from stronger initial treatment responses rather than a permanently different biology.
What Happens With Each Recurrence
One of the hardest realities of recurrent ovarian cancer is that each subsequent recurrence tends to arrive sooner than the last. If a first remission lasted 18 months, the second might last 12, and the third even less. Each line of chemotherapy also tends to produce a lower response rate. This pattern of progressively shorter remissions is typical, though not universal.
Platinum sensitivity remains a useful predictor through at least the third recurrence, meaning that women whose cancer keeps responding to platinum drugs continue to have better outcomes at each stage. Treatment itself remains beneficial: receiving therapy for recurrence was found to independently predict overall survival through at least the fifth recurrence, suggesting that continuing to treat each relapse still extends life even when remissions grow shorter.
Surgery for Recurrent Disease
For carefully selected patients, a second surgery to remove as much visible cancer as possible can dramatically improve survival. One study found a median survival of 88 months (more than seven years) in women who had successful secondary surgery, compared to 41 months for those treated with chemotherapy alone. The key word is “selected.” Not every recurrence is operable, and the benefit depends on whether the surgeon can remove all visible disease. Women with a single site of recurrence, a long first remission, and good overall health are the strongest candidates.
How Newer Treatments Are Changing Outcomes
PARP inhibitors have become a major part of treatment for recurrent ovarian cancer, particularly for women with BRCA mutations or platinum-sensitive disease. In the SOLO2 trial, the PARP inhibitor olaparib extended median overall survival by about 13 months compared to placebo in women with platinum-sensitive relapsed disease. However, results have been mixed across different drugs in this class, and not all trials have shown a clear survival benefit despite significantly delaying disease progression.
Immunotherapy, specifically checkpoint inhibitors that help the immune system recognize cancer cells, has produced more modest results in ovarian cancer than in some other tumor types. Response rates for single-agent immunotherapy in recurrent ovarian cancer range from only 10 to 15 percent. Median overall survival after receiving immunotherapy was about 18 months in one study, but this field is still evolving as researchers test combination approaches.
Putting the Numbers in Context
For reference, the National Cancer Institute reports a five-year relative survival rate of 31.5% for ovarian cancer diagnosed at a distant stage (meaning it has already spread beyond the ovaries). Most recurrences fall into this category since the disease typically returns in the abdominal cavity. This figure captures both women at initial diagnosis and those managing recurrence, so it serves as a rough baseline rather than a precise prediction for any individual.
What makes recurrent ovarian cancer survival so variable is the combination of factors at play. A woman with a BRCA mutation whose platinum-sensitive cancer recurs at a single site after a long remission, and who is a candidate for secondary surgery, has a fundamentally different outlook than a woman with platinum-resistant disease and multiple sites of recurrence. The median figures of 9 to 24 months represent the middle of a wide spectrum, and individual outcomes can fall well outside that range in either direction.
The most actionable thing to understand is that platinum sensitivity and the length of each remission are the strongest signals of what comes next. These factors guide which treatments your oncologist recommends and provide the most reliable framework for understanding prognosis at each stage of the disease.